Insuvia is delighted to announce the opening of our new office in Baku, Azerbaijan. The decision to open an office in Azerbaijan was based on the visible growth of the pharmaceutical market in the CIS region, changes in the legal framework and the willingness to assist prospective and existing life-science companies in this market by providing them with our pharmacovigilance or regulatory affairs services.
“The decision to expand into the CIS region, was a logical step in our business growth strategy,” said Donatas Grina, CEO of Insuvia. “With a presence in Azerbaijan, we will strengthen our existing support to life-science companies in the CIS region and broaden our geographical footprint which is relevant to pharmaceutical companies seeking to establish themselves in new emerging markets.”
“Each of our strategic steps is done primarily with our customer needs in mind. We sincerely believe that by opening this office, we will be able to provide pharmacovigilance and regulatory affairs support to our clients in the CIS region, maintain the already strong business relationships and establish new ones that we will nurture in the future”- Martynas Juzenas, COO of Insuvia.
Insuvia is designed to act as a pharmacovigilance and regulatory affairs unit for pharmaceutical companies in those countries and regions, where they have no internal structures or decide to focus their resources on commercial activities. In this context, we provide the regional and country-level expertise to solve all pharmacovigilance and regulatory affairs challenges that pharmaceutical companies encounter while commercializing their products.
If you have any additional questions contact us!